Cargando…

Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading

In Alzheimer’s disease (AD), younger symptom onset is associated with accelerated disease progression and tau spreading, yet the mechanisms underlying faster disease manifestation are unknown. To address this, we combined resting-state fMRI and longitudinal tau-PET in two independent samples of cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frontzkowski, Lukas, Ewers, Michael, Brendel, Matthias, Biel, Davina, Ossenkoppele, Rik, Hager, Paul, Steward, Anna, Dewenter, Anna, Römer, Sebastian, Rubinski, Anna, Buerger, Katharina, Janowitz, Daniel, Binette, Alexa Pichet, Smith, Ruben, Strandberg, Olof, Carlgren, Niklas Mattsson, Dichgans, Martin, Hansson, Oskar, Franzmeier, Nicolai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392750/ https://www.ncbi.nlm.nih.gov/pubmed/35987901 http://dx.doi.org/10.1038/s41467-022-32592-7

Ejemplares similares

Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals
por: Biel, Davina, et al.
Publicado: (2021)

Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease
por: Franzmeier, Nicolai, et al.
Publicado: (2020)

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease
por: Biel, Davina, et al.
Publicado: (2023)

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
por: Rubinski, Anna, et al.
Publicado: (2022)

Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease
por: Biel, Davina, et al.
Publicado: (2022)

KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer’s disease
por: Neitzel, Julia, et al.
Publicado: (2021)

Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
por: Franzmeier, Nicolai, et al.
Publicado: (2020)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory
por: Franzmeier, Nicolai, et al.
Publicado: (2019)

FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
por: Rubinski, Anna, et al.
Publicado: (2020)

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
por: Leuzy, Antoine, et al.
Publicado: (2021)

Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
por: Leuzy, Antoine, et al.
Publicado: (2023)

Disentangling the effects of Alzheimer’s and small vessel disease on white matter fibre tracts
por: Dewenter, Anna, et al.
Publicado: (2022)

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
por: Horie, Kanta, et al.
Publicado: (2023)

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
por: Smith, Ruben, et al.
Publicado: (2020)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
por: Salvadó, Gemma, et al.
Publicado: (2023)

Tau accumulation and its spatial progression across the Alzheimer’s disease spectrum
por: St-Onge, Frédéric, et al.
Publicado: (2023)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Age-related and amyloid-beta-independent tau deposition and its downstream effects
por: Wuestefeld, Anika, et al.
Publicado: (2023)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease
por: Ossenkoppele, Rik, et al.
Publicado: (2019)

Tau deposition patterns are associated with functional connectivity in primary tauopathies
por: Franzmeier, Nicolai, et al.
Publicado: (2022)

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
por: Leuzy, Antoine, et al.
Publicado: (2020)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s disease
por: Salvadó, Gemma, et al.
Publicado: (2023)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Trait Mindfulness Is Associated With Less Amyloid, Tau, and Cognitive Decline in Individuals at Risk for Alzheimer’s Disease
por: Strikwerda-Brown, Cherie, et al.
Publicado: (2022)

Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition
por: Cullen, Nicholas C., et al.
Publicado: (2021)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study
por: Mattsson, Niklas, et al.
Publicado: (2018)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
por: Ossenkoppele, Rik, et al.
Publicado: (2022)

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vva6v1c8cks34llqquu6sol1kb